Research & Development

FDA fast-tracks Alto Neuroscience’s ALTO-101 for CIAS treatment

The US Food and Drug Administration (FDA) has awarded Fast Track designation to Alto Neuroscience’s ALTO-101, a novel small molecule phosphodiesterase-4 (PDE4) inhibitor for the treatment of cognitive impairment linked to schizophrenia (CIAS).

BioLineRx partners with Hemispherian to advance brain cancer therapy

BioLineRx and Hemispherian have formed a joint venture to advance the development of GLIX1, an oral small molecule aimed at targeting DNA damage response in glioblastoma (GBM) and other types of cancer.

Argo Biopharma secures NMPA clearance for Phase II PNH trial

Argo Biopharmaceutical has received investigational new drug (IND) approval from the National Medical Products Administration (NMPA) of China for a Phase II clinical trial of BW-40202 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Dewpoint Therapeutics secures funding for DPTX3186 development

Dewpoint Therapeutics has secured funding in a Series D funding round, which will support the progression of DPTX3186, a condensate modulator (c-mod), into clinical studies by 2025-end.

Novonesis and Novo Nordisk collaborate on gut microbiome research initiative

Novonesis and Novo Nordisk have formed a research partnership to investigate the role of the gut microbiome in sustaining metabolic health.

FDA grants breakthrough therapy status to Eli Lilly’s olomorasib

Eli Lilly has received the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, an investigational KRAS G12C inhibitor.

OMass signs deal with Genentech for IBD small molecules

OMass Therapeutics in the UK has signed an exclusive collaboration and licensing agreement with Roche Group member Genentech to develop and commercialise inflammatory bowel disease (IBD) therapies.

Biosynth opens expanded GMP bioconjugation facility in Germany

Biosynth, a supplier of essential raw materials and services for the life sciences and diagnostics sectors, has opened an expanded good manufacturing practice (GMP) bioconjugation facility at its Berlin site in Germany.

PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea

PCI Pharma Services (PCI) has concluded the acquisition of Ajinomoto Althea, a sterile fill-finish contract development and manufacturing organisation (CDMO) based in the US.